- Bioventus press release (BVS): Q3 Non-GAAP EPS of $0.15 beats by $0.03.
- Revenue of $138.7M (-0.2% Y/Y) beats by $0.51M.
- Guidance:
- Net sales of $560 million to $570 million. This reflects organic* growth of approximately 6.1% to 8.0% when including the impact of the Company's divestiture
Bioventus Non-GAAP EPS of $0.15 beats by $0.03, revenue of $138.7M beats by $0.51M
4 hours ago
1
Related
Prediction market odds of U.S. shutdown lasting the month sl...
4 minutes ago
0
Sumitomo Chemical Company reports Q2 results
4 minutes ago
0
Nuveen Credit Strategies Income Fund declares $0.054 dividen...
5 minutes ago
0
A risky mortgage instrument that helped spark the Great Fina...
6 minutes ago
0
Nuveen Floating Rate Income Fund declares $0.085 dividend
7 minutes ago
0
Charles River Laboratories Q3 2025 Earnings Preview
8 minutes ago
0
Perrigo Q3 2025 Earnings Preview
9 minutes ago
0
Martha Stewart responds to Gen Z paying up to $1,700 for her...
9 minutes ago
0
Zimmer Biomet Q3 2025 Earnings Preview
10 minutes ago
0
Cresco Labs Q3 2025 Earnings Preview
10 minutes ago
0
Waters raises 2025 sales growth outlook to 7% midpoint as in...
10 minutes ago
0
Recursion Pharmaceuticals Q3 2025 Earnings Preview
11 minutes ago
0
IAC signals 7–10% digital revenue growth for Q4 2025 with ac...
12 minutes ago
0
Uber says ‘unpredictable’ issues involving ‘legal proceeding...
17 minutes ago
0
Bio-Techne Q1 2026 Earnings Preview
17 minutes ago
0
Teva Pharmaceutical Q3 2025 Earnings Preview
19 minutes ago
0
Delaware court won't rule on Pfizer/Novo battle for Metsera ...
20 minutes ago
0
TriplePoint Venture Growth BDC Q3 2025 Earnings Preview
20 minutes ago
0
LifeX 2050 Inflation-Protected Longevity Income ETF declares...
25 minutes ago
0
Nuveen Pennsylvania Quality Municipal Income Fund declares $...
27 minutes ago
0
Trending
Popular
© FBT Company 2025. All rights are reserved







English (US) ·